Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 487-494

  Turpin, Jim A ^a   Buckheit Jr , Robert W ^b   Derse, David ^c   Hollingshead, Melinda ^c   Williamson, Karen ^a   Palamone, Carla ^a   Osterling, M Clayton ^b   Hill, Shawn A ^c   Graham, Lisa ^a   Schaeffer, Catherine A ^a   Bu, Ming ^a   Huang, Mingjun ^a   Cholody, Wieslaw M ^c   Michejda, Christopher J ^c   Rice, William G ^a  

^a SAIC FREDERICK INC   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REV PROTEIN; TEMACRAZINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

EID: 0031893416     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.487     Document Type: Article

References (41)

1. Andrews, J. M., G. C. Newbound, M. Oglesbee, J. N. Brady, and M. D. Lairmore. 1997. The cellular stress response enhances human T-cell lymphotropic virus type 1 basal gene transcription through the core promoter region of the long terminal repeat. J. Virol. 71:741-745.
2. Baba, M., M. Okamoto, M. Makino, Y. Kimura, T. Ikeuchi, T. Sakaguchi, and T. Okamoto. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
3. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, W. A. Harrison, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
4. Buckheit, R. W., Jr., J. L. Roberson, C. Lackman-Smith, J. R. Wyatt, T. A. Vickers, and D. J. Ecker. 1994. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10:1497-1506.
5. Bushman, F. D., and R. Craigie. 1991. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 88:1339-1343.
6. Butera, S. T., B. D. Roberts, J. W. Critchfield, G. Fang, T. McQuade, S. J. Gracheck, and T. M. Folks. 1995. Compounds that target novel cellular components in HIV-1 transcription. Mol. Med. 1:758-767.
7. Carroll, R., L. Martarano, and D. Derse. 1991. Identification of lentivirus Tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras. J. Virol. 65:3460-3467.
8. Cholody, W. M., L. Hernandez, L. Hassner, D. A. Scudiero, D. B. Djurickovic, and C. J. Michejda. 1995. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors. J. Med. Chem. 38:3043-3052.
9. Clanton, D. J., R. W. Buckheit, Jr., S. J. Terpening, R. Kiser, N. Mongelli, A. L. Borgia, R. Schultz, V. Narayanan, J. P. Bader, and W. G. Rice. 1995. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antivir. Res. 27:335-354.
10. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T-cell clone. J. Immunol. 142:431-438.
11. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267:483-489.
12. Cohen, J. 1997. The daunting challenge of keeping HIV suppressed. Science 277:32-33.
13. Cujec, T. P., H. Cho, E. Maldonado, J. Meyer, D. Reinberg, and B. M. Peterlin. 1997. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17: 1817-1823.
14. Farnet, C. M., B. Wang, J. R. Lipford, and F. D. Bushman. 1996. Differential inhibition of HIV-1 preintegration complexes and purified protein by small molecules. Proc. Natl. Acad. Sci. USA 93:9742-9747.
15. Felber, B. K., and G. N. Pavlakis. 1988. A quantitative bioassay for HIV-1 based on transactivation. Science 239:184-186.
16. Folks, T. M., J. Justement, A. Kinter, S. Schnittman, J. Orenstein, G. Poli, and A. S. Fauci. 1988. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J. Immunol. 140:1117-1122.
17. Hamy, F., E. R. Felder, G. Heizmann, J. Lazdins, F. Aboul-ela, G. Varani, J. Karn, and T. Klimkait. 1997. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 94:3548-3553.
18. Hernandez, L., W. M. Cholody, E. A. Hudson, J. H. Resau, G. Pauly, and C. J. Michejda. 1995. Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Res. 55: 2338-2345.
19. Herrmann, C. H., and A. P. Rice. 1995. Lentivirus Tat proteins specifcally associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-1629.
20. Hollingshead, M., J. Robertson, W. Decker, R. Buckheit, Jr., C. Elder, L. Malspeis, J. Mayo, and M. Grever. 1995. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice. Antivir. Res. 28:265-279.
21. Hope, T. J., X. J. Huang, D. McDonald, and T. G. Parslow. 1990. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc. Natl. Acad. Sci. USA 87:7787-7791.
22. Hsu, M.-C., U. Dhingra, J. V. Earley, M. Holly, D. Keith, C. M. Nalin, A. R. Richou, A. D. Schutt, S. Y. Tam, M. J. Potash, D. J. Volsky, and D. D. Richman. 1993. Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. USA 90:6395-6399.
23. Kageyama, S., T. Mimoto, Y. Murakawa, M. Nomizu, H. Ford, Jr., T. Shirasaka, S. Gulnik, J. Erickson, K. Takada, H. Hayashi, S. Broder, Y. Kiso, and H. Mitsuya. 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37:810-817.
24. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Nobeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
25. Kariya, Y., K. Kato, Y. Hayashizaki, S. Himeno, S. Tarui, and K. Matsubara. 1987. Revision of consensus sequence of human Alu repeats - a review. Gene 53:1-10.
26. Kingston, R. E. 1996. Current protocols in molecular biology, p. 9.7.5. John Wiley & Sons, Inc., New York, N.Y.
27. LaFemina, R. L., P. L. Graham, K. LeGrow, J. C. Hastings, A. Wolfe, S. D. Young, E. A. Emini, and D. J. Hazuda. 1995. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antibicrob. Agents Chemother. 39:320-324.
28. Michejda, C. J., L. Hernandez, W. M. Cholody, and J. A. Turpin. Unpublished data.
29. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
30. Pomerantz, R. J., D. Trono, M. B. Feinberg, and D. Baltimore. 1990. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 61:1271-1276.
31. Rice, W. G., D. Baker, L. Field, C. A. Schaeffer, L. Graham, M. Bu, S. Terpening, D. Clanton, R. Schultz, J. P. Bader, R. W. Buckheit, Jr., L. Field, P. K. Singh, and J. A. Turpin. 1997. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 41:419-426.
32. Rice, W. G., C. A. Schaeffer, L. Graham, M. Bu, J. S. McDougal, S. L. Orloff, F. Villinger, M. Young, S. Oroszlan, M. R. Fesen, Y. Pommier, J. Mendeleyev, and E. Kun. 1993. The site of action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in lymphocytes. Proc. Natl. Acad. Sci. USA 90:9721-9724.
33. Rice, W. G., J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. J. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sowder II, L. O. Arthur, and L. E. Henderson. 1995. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270:1194-1197.
34. Rice, W. G., J. A. Turpin, M. Huang, D. Clanton, R. W. Buckheit, Jr., D. G. Covell, A. Wallqvist, N. McDonnell, R. N. De Guzman, M. F. Summers, L. Zalkow, J. P. Bader, R. D. Haugwitz, and E. A. Sausville. 1997. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nature Med. 3:341-345.
35. Saltarelli, M. J., E. Hadziyannis, C. E. Hart, J. V. Harrison, B. K. Felber, T. J. Spira, and G. N. Pavlakis. 1996. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. AIDS Res. Hum. Retroviruses 12:1443-1456.
36. Stevens, S. W., and J. D. Griffith. 1996. Sequence analysis of the human DNA flanking sites of human immunodeficiency virus type 1 integration. J. Virol. 70:6459-6462.
37. Stevenson, M., M. Bukrinsky, and S. Haggerty. 1992. HIV-1 replication and potential targets for intervention. AIDS Res. Hum. Retroviruses 2:107-117.
38. Turpin, J. A., S. J. Terpening, C. A. Schaeffer, G. Yu, C. J. Glover, R. L. Felsted, E. A. Sausville, and W. G. Rice. 1996. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of Gag precursors and result in the release of noninfectious virus particles. J. Virol. 70:6180-6189.
39. Wu-Baer, F., W. S. Lane, and R. B. Gaynor. 1995. The cellular factor TRP-185 regulates RNA polymerase binding to HIV-1 TAR RNA. EMBO J. 14:5995-6009.
40. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
41. Zhou, Q., and P. A. Sharp. 1996. Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 274:605-610.